研究单位：[1]Fourth Affiliated Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050011[2]Jiangsu HengRui Medicine Co., Ltd.
研究目的：
The purpose of this study is to assess the efficacy and safety of apatinib as maintenance therapy after first-line chemotherapy in Postoperative Recurrence / Metastasis Progressive Gastric Cancer.
